BioMedNewsBreaks — Adageis Brings Power of AI to the Frontlines of Healthcare

Adageis is positioning as a key player in healthcare financial technology, offering an innovative AI-powered ProActive Care Platform that helps providers transition from fee-for-service to value-based care models. Its Patented Risk Engine (“PRE”) enables predictive analytics for optimizing revenue, improving patient outcomes, and simplifying insurance complexities. By seamlessly integrating with widely used systems, the platform delivers an easy-to-use, efficient, and scalable solution for value-based care revenue optimization. With streamlined onboarding, projected growth and funding, Adageis is poised for significant expansion in the healthcare technology space, offering investors a compelling opportunity to participate in the evolving $19.27 billion healthcare AI market.

To view the full article, visit https://ibn.fm/AhOwj

About Adageis
Adageis is a healthcare technology innovator focused on addressing inefficiencies in care delivery through AI and machine learning. Its solutions empower healthcare providers and healthcare organizations to enhance patient outcomes, streamline operations, and drive increased revenue through meeting the demands of value-based care. By integrating advanced technologies with minimal disruption, Adageis remains a leader in driving meaningful change across the healthcare sector. For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Engages DUCK FLATS Pharma for IND Readiness and Regulatory Execution

Oragenics (NYSE American: OGEN) announced that it has engaged DUCK FLATS Pharma as its U.S.…

23 hours ago

BioMedNewsBreaks – Oragenics Inc. (NYSE American: OGEN) Participates in SCOPE Summit 2026 Ahead of Phase 2a Concussion Trial

Oragenics (NYSE American: OGEN), a clinical-stage biotechnology company developing intranasal therapeutics for neurological disorders, announced…

2 days ago

BioMedNewsBreaks – NanoViricides (NYSE American: NNVC) Highlights Mission Matters Podcast Interview With President Anil Diwan

NanoViricides, Inc. (NYSE American: NNVC) announced that President Dr. Anil R. Diwan was interviewed on…

2 days ago

BioMedNewsBreaks — VolitionRx (NYSE American: VNRX) Prepares Reimbursement Submission for Nu.Q Cancer Assays in France

VolitionRx Ltd. (NYSE American: VNRX) (“Volition”), a multi-national epigenetics company, announced that it is preparing a reimbursement submission for its Nu.Q®…

5 days ago

BioMedNewsBreaks — Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW) Highlights Board Appointments and AVERSA Fentanyl Milestones From Annual Meeting 

Nutriband (NASDAQ: NTRB) (NASDAQ: NTRBW) provided shareholders with an update following its 2026 Annual Shareholders Meeting held Jan. 24, 2026,…

5 days ago

BioMedNewsBreaks — Soligenix Inc. (NASDAQ: SNGX) Targets Critical Gaps in CTCL Treatment with HyBryte(TM) 

Cutaneous T-cell lymphoma, or CTCL, is recognized by clinicians as one of the most difficult…

6 days ago